These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 33616313)
21. Lenvatinib for the treatment of renal cell carcinoma. Roviello G; Corona SP; Bozza G; Aieta M; Generali D; Rodriquenz MG; Mileo AM; Imperatori M; Ianza A; Conca R; Sobhani N Expert Opin Investig Drugs; 2018 May; 27(5):507-512. PubMed ID: 29718721 [TBL] [Abstract][Full Text] [Related]
22. [Medical treatment of renal cell carcinoma]. Guy L; Bay JO; Bastide C; Mahammedi H; Bruyere F; Karsenty G Prog Urol; 2013 Nov; 23(15):1225-37. PubMed ID: 24183081 [TBL] [Abstract][Full Text] [Related]
23. Proof of efficacy is not enough: contemporary management of patients with metastatic renal cell carcinoma with targeted therapy. Sun M; Bianchi M; Hansen J; Trinh QD; Karakiewicz PI J Clin Oncol; 2012 Nov; 30(31):3901; author reply 3902. PubMed ID: 22987077 [No Abstract] [Full Text] [Related]
24. Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy? De Lisi D; De Giorgi U; Lolli C; Schepisi G; Conteduca V; Menna C; Tonini G; Santini D; Farolfi A Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):461-467. PubMed ID: 29557694 [TBL] [Abstract][Full Text] [Related]
25. Recommendations on managing lenvatinib and everolimus in patients with advanced or metastatic renal cell carcinoma. Grande E; Glen H; Aller J; Argenziano G; Lamas MJ; Ruszniewski P; Zamorano JL; Edmonds K; Sarker S; Staehler M; Larkin J Expert Opin Drug Saf; 2017 Dec; 16(12):1413-1426. PubMed ID: 28920492 [TBL] [Abstract][Full Text] [Related]
26. Is there a role for novel TKI/ICI combinations in metastatic renal cell carcinoma? Definitely maybe. Meza L; Bergerot PG; Agarwal N; Pal SK Ann Oncol; 2021 Jan; 32(1):12-14. PubMed ID: 33121996 [No Abstract] [Full Text] [Related]
36. [Management of side effects associated with antiangiogenic treatment in renal cell carcinoma]. Fléchon A; Boyle H; Négrier S Bull Cancer; 2010; 97():73-82. PubMed ID: 20418206 [TBL] [Abstract][Full Text] [Related]
37. An update on targeted therapy in metastatic renal cell carcinoma. Lombardi G; Zustovich F; Donach M; Dalla Palma M; Nicoletto O; Pastorelli D Urol Oncol; 2012; 30(3):240-6. PubMed ID: 20456985 [TBL] [Abstract][Full Text] [Related]
38. Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus. Matsuki M; Adachi Y; Ozawa Y; Kimura T; Hoshi T; Okamoto K; Tohyama O; Mitsuhashi K; Yamaguchi A; Matsui J; Funahashi Y Cancer Sci; 2017 Apr; 108(4):763-771. PubMed ID: 28107584 [TBL] [Abstract][Full Text] [Related]
39. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394 [TBL] [Abstract][Full Text] [Related]